| Bioactivity | Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) prodrug in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF). Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS)[1]. | ||||||||||||
| Name | Diroximel fumarate | ||||||||||||
| CAS | 1577222-14-0 | ||||||||||||
| Formula | C11H13NO6 | ||||||||||||
| Molar Mass | 255.22 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Angela Wehr, et al. Relative Bioavailability of Monomethyl Fumarate after Administration of ALKS 8700 in Healthy Subjects (P1.403). Neurology. Apr 2018. |
Diroximel fumarate
CAS: 1577222-14-0 F: C11H13NO6 W: 255.22
Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) prodrug in a controlled-
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.